BEX2

Across TCGA pan-cancer cohorts, BEX2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BEX2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BEX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BEX2 expression acts as an unfavorable survival marker.

CCRCC and LUAD are the cancer types where BEX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.207	0.961	.024	13	view →
LUAD	OS	Median	All	0.589	0.873	.006	5	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BEX2–CCRCC (DFS)

Open the CCRCC breakdown →